Design Therapeutics, Inc.
DSGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807120
No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Design Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 79 | 1 | 83 | +5 |
| Shares | 39.9M | 44 | 40.4M | +462.0K (+1.2%) |
| Value | $667.2M | $1.00K | $414.2M | −$253.1M (−37.9%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Design Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 156,027 | $1.60M | 0.00% |
| Marshall Wace, LLP | 112,818 | $1.16M | 0.00% |
| Cubist Systematic Strategies, LLC | 109,303 | $1.12M | 0.01% |
| Acadian Asset Management LLC | 57,957 | $594.0K | 0.00% |
| Silverarc Capital Management, LLC | 57,025 | $585.1K | 0.20% |
| Two Sigma Investments, LP | 35,093 | $360.1K | 0.00% |
| Jump Financial, LLC | 30,400 | $311.9K | 0.02% |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd. | 16,689 | $163.1K | 0.00% |
| Gsa Capital Partners LLP | 13,619 | $140.0K | 0.02% |
| E Fund Management Co., Ltd. | 12,523 | $128.0K | 0.01% |
| Envestnet Asset Management Inc | 12,236 | $125.5K | 0.00% |
| Ikarian Capital, LLC | 11,568 | $118.7K | 0.05% |
| Walleye Capital LLC | 10,703 | $109.8K | 0.00% |
| Dark Forest Capital Management LP | 1,669 | $17.1K | 0.00% |
| High Net Worth Advisory Group LLC | 1,000 | $10.3K | 0.00% |
| Federated Hermes, Inc. | 744 | $7.63K | 0.00% |
| Group One Trading, L.P. | 500 | $5.13K | 0.00% |
| TCI Wealth Advisors, Inc. | 84 | $862 | 0.00% |
| CWM, LLC | 24 | $0 | 0.00% |
Sold out (14)
Institutions that held Design Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Tekla Capital Management LLC | 280,523 | $4.69M |
| Price T Rowe Associates Inc | 280,120 | $4.68M |
| Integral Health Asset Management, LLC | 125,000 | $2.09M |
| HighVista Strategies LLC | 38,152 | $638.0K |
| DekaBank Deutsche Girozentrale | 18,700 | $317.0K |
| TD Asset Management Inc | 16,318 | $274.0K |
| Trexquant Investment LP | 11,296 | $189.0K |
| Balyasny Asset Management LLC | 11,134 | $186.0K |
| Invesco Ltd. | 10,058 | $168.0K |
| SG Americas Securities, LLC | 9,936 | $166.0K |
| Wells Fargo & Company | 406 | $7.00K |
| Howe & Rusling Inc | 70 | $1.00K |
| Nisa Investment Advisors, LLC | 34 | $1.00K |
| Lindbrook Capital, LLC | 78 | $1.00K |
Not filed for Q4 2022 yet (1)
Institutions that held Design Therapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| FourThought Financial, LLC | 44 | $1.00K |